Cite
HARVARD Citation
Saji, S. et al. (2022). Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031). Japanese journal of clinical oncology. pp. 1124-1133. [Online].